4.7 Article

Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 59, Issue 12, Pages 5911-5916

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b00140

Keywords

-

Funding

  1. National Natural Science Foundation of China [81425021, 21572230]
  2. Natural Science Foundation of Guangdong Province [2015A03031201]
  3. AbbVie
  4. Bayer Pharma AG
  5. Boehringer Ingelheim
  6. Canada Foundation for Innovation
  7. Eshelman Institute for Innovation
  8. Genome Canada
  9. Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant] [115766]
  10. Janssen
  11. Novartis Pharma AG
  12. Ontario Ministry of Economic Development and Innovation
  13. Pfizer
  14. Sao Paulo Research Foundation-FAPESP
  15. Takeda
  16. Wellcome Trust [092809/Z/10/Z]
  17. Merck Co.

Ask authors/readers for more resources

The structure-based design of 1, 2, 3, 4-tetrahydroisoquinoline derivatives as selective DDR1 inhibitors is reported. One of the representative compounds, 6j, binds to DDR1 with a K-d value of 4.7 nM and suppresses its kinase activity with an IC50 value of 9.4 nM, but it is significantly less potent for a panel of 400 nonmutated kinases. 6j also demonstrated reasonable pharmacokinetic properties and a promising oral therapeutic effect in a bleomycin-induced mouse pulmonary fibrosis model.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available